Becton, Dickinson and Company (NYSE:BDX - Get Free Report)'s stock price hit a new 52-week high on Tuesday . The stock traded as high as $193.07 and last traded at $190.5840, with a volume of 1310991 shares trading hands. The stock had previously closed at $192.00.
Wall Street Analyst Weigh In
BDX has been the subject of a number of recent analyst reports. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Bank of America reduced their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Barclays upped their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a report on Monday, May 11th. Royal Bank Of Canada raised their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a report on Thursday, August 13th. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $185.67.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
Becton, Dickinson and Company Trading Down 0.7%
The company has a market capitalization of $52.51 billion, a P/E ratio of 57.40, a PEG ratio of 13.53 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a fifty day moving average of $162.48 and a 200 day moving average of $160.73.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company's revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is presently 126.51%.
Insiders Place Their Bets
In related news, EVP Michael David Garrison sold 1,100 shares of the firm's stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company's stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company's stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 11,704 shares of company stock valued at $1,963,618 over the last three months. 0.40% of the stock is owned by company insiders.
Hedge Funds Weigh In On Becton, Dickinson and Company
Large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its stake in Becton, Dickinson and Company by 14,668.6% in the second quarter. California State Teachers Retirement System now owns 69,907,953 shares of the medical instruments supplier's stock valued at $10,579,171,000 after buying an additional 69,434,598 shares during the last quarter. Auto Owners Insurance Co grew its stake in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the period. Vanguard Group Inc. increased its holdings in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after buying an additional 4,223,149 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $3,721,533,000. Finally, State Street Corp grew its holdings in Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier's stock valued at $2,714,871,000 after purchasing an additional 116,737 shares during the period. 86.97% of the stock is currently owned by institutional investors.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
